<unk> s can be used to compare the effectiveness of treatments. Use of<unk> -year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer. Improvements in<unk> s are sometimes attributed to improvements in diagnosis rather than to improvements in prognosis. To compare treatments independently from diagnostics, it may be better to consider survival from reaching a certain stage of the disease or its treatment. Analysis performed against the Surveillance, Epidemiology, and End Results database (SEER) facilitates calculation of<unk> s.
Five-year survival rate
Survival rate
Progression-free survival
Response evaluation criteria in solid tumors
Prognosis
Cancer slope factor
TNM staging system
Post-transplant survival measure